Tags: multiple | sclerosis | drug | works | succeeds | ozanimod

Multiple Sclerosis Drug Works in Late-Stage Trial

Image: Multiple Sclerosis Drug Works in Late-Stage Trial
(Copyright Fotolia)

Monday, 22 May 2017 08:57 AM

Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal of reducing annualized relapse rate, when compared to Biogen Inc's Avonex, in a second late-stage study.

The drug, ozanimod, succeeded in another late-stage study in February.

Celgene said on Monday it expected to file for U.S. marketing application by the end of this year.

Ozanimod is also being tested for ulcerative colitis and Crohn's disease.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Health-News
Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal of reducing annualized relapse rate, when compared to Biogen Inc's Avonex, in a second late-stage study.The drug, ozanimod, succeeded in another late-stage study in February.Celgene said...
multiple, sclerosis, drug, works, succeeds, ozanimod
70
2017-57-22
Monday, 22 May 2017 08:57 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved